6-溴-4-二氢色原酮 | 49660-57-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡喃类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 6-溴-4-二氢色原酮
• 中文别名: 6-溴-2,3-二氢-4H-苯并吡喃-4-酮；6-溴-2,3-二氢苯并吡喃-4-酮；6-溴苯并吡喃酮；6-溴-4-色原酮
• 英文名称: 6-bromochroman-4-one
• 英文别名: 6-bromo-2,3-dihydro-4H-chromen-4-one；6-bromo-2,3-dihydrochromen-4-one；6-bromochromanone；6-Brom-chroman-4-on
• CAS: 49660-57-3
• 化学式: C₉H₇BrO₂
• mdl: MFCD00546803
• 分子量: 227.057
• InChiKey: PFLPVOXSUCCZDH-UHFFFAOYSA-N

物化性质

• 熔点：
  77-83°C
• 沸点：
  336.6±42.0 °C(Predicted)
• 密度：
  1.621±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• WGK Germany：
  3
• 危险品运输编号：
  NONH for all modes of transport
• 海关编码：
  2932999099
• 危险标志：
  GHS07
• 危险性描述：
  H302
• 危险性防范说明：
  P280,P305+P351+P338
• 储存条件：
  | 室温 |

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 6-Bromo-4-chromanone
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 49660-57-3
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Synonyms : 6-Bromo-2,3-dihydro-4H-chromen-4-one
Formula : C9H7BrO2
Molecular Weight : 227,05 g/mol
CAS-No. : 49660-57-3
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
6-BROMO-4-CHROMANONE
Acute Tox. 4; H302 -
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
6-BROMO-4-CHROMANONE
Xn, R22 -
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Hydrogen bromide gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Handle and store under inert gas. Heat-, light-, and moisture-sensitive.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into
the environment must be avoided.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 77 - 83 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,310
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
Toxic to aquatic life.

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

4-二氢色原酮是一类具有优良生物活性的天然化合物，具备优异的抗癌、抗菌、抗炎和抗变态反应活性，以及抗血小板凝聚等作用。6-溴-4-二氢色原酮则是其衍生物，可用作医药中间体。

反应信息

• 作为反应物：
  描述：

  6-溴-4-二氢色原酮 在 吡啶 、 二氯双[二叔丁基-(4-二甲基氨基苯基)膦]钯(II) 、 盐酸羟胺 、 四丁基硫酸氢铵 、 三氯化硼 、 potassium carbonate 、 sodium hydroxide 作用下， 以 二氯甲烷 、 醋酸异丙酯 、 水 、 甲苯 为溶剂， 生成 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one
  参考文献：
  名称：

  PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS

  摘要：

  本公开提供了制备以下化合物的过程：这是一种选择性晚期钠电流抑制剂。该公开还提供了合成中间体化合物。

  公开号：

  US20150225384A1
• 作为产物：
  描述：

  3-苯氧基丙腈 在 盐酸 、 N-溴代丁二酰亚胺(NBS) 、 硫酸 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 14.0h， 生成 6-溴-4-二氢色原酮
  参考文献：
  名称：

  一种六溴四氢色原酮的合成新方法

  摘要：

  本发明公开了一种六溴四氢色原酮的合成方法，是在反应溶剂中，以苯酚和丙烯腈反应原料，在有机药品作用下，反应得到六溴四氢色原酮。本发明反应条件温和，原料易得价廉，产物的价值非常高。本发明合成的六溴四氢色原酮具有非常高的药用价值，有利于糖尿病、肥胖症、神经系统疾病等领域的新药的研制与开发，有着广泛的用途和应用市场。

  公开号：

  CN106699716A

文献信息

• Chemoselective Hydrosilylation of the α,β-Site Double Bond in α,β- and α,β,γ,δ-Unsaturated Ketones Catalyzed by Macrosteric Borane Promoted by Hexafluoro-2-propanol
  作者：Xiao-Yu Zhan、Hua Zhang、Yu Dong、Jian Yang、Shuai He、Zhi-Chuan Shi、Lei Tang、Ji-Yu Wang

  DOI：10.1021/acs.joc.0c00568

  日期：2020.5.15

  The B(C6F5)3-catalyzed chemoselective hydrosilylation of α,β- and α,β,γ,δ-unsaturated ketones into the corresponding non-symmetric ketones in mild reaction conditions is developed. Nearly 55 substrates including those bearing reducible functional groups such as alkynyl, alkenyl, cyano, and aromatic heterocycles are chemoselectively hydrosilylated in good to excellent yields. Isotope-labeling studies

  在温和的反应条件下，由B（C6F5）3催化的α，β-和α，β，γ，δ-不饱和酮的化学选择性氢化硅烷化为相应的不对称酮。将近55种底物，包括带有可还原官能团（例如炔基，烯基，氰基和芳香族杂环）的底物，以良好或优异的产率进行化学选择性氢化硅烷化。同位素标记研究表明，六氟-2-丙醇在该过程中也用作氢源。
• Discovery of 3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one derivatives as a new class of ROCK inhibitors for the treatment of glaucoma
  作者：Yumeng Sun、Yueshan Li、Zhuang Miao、Ruicheng Yang、Yun Zhang、Ming Wu、Guifeng Lin、Linli Li

  DOI：10.1016/j.bmcl.2021.128138

  日期：2021.8

  associated with the pathology of glaucoma and discovery of ROCK inhibitors has attracted much attention in recent years. Herein, we report a series of 3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one derivatives as a new class of ROCK inhibitors. Structure-activity relationship studies led to the discovery of compound 12b, which showed potent activities against ROCK I and ROCK Ⅱ with IC50 values of 93 nM

  Rho 相关蛋白激酶 (ROCK) 与青光眼的病理学相关，近年来 ROCK 抑制剂的发现引起了广泛关注。在此，我们报告了一系列 3,4-二氢苯并[ f ][1,4] oxazep​​in-5(2 H )-one 衍生物作为一类新的 ROCK 抑制剂。构效关系研究导致了化合物12b的发现，该化合物对 ROCK I 和 ROCK Ⅱ具有强活性，IC 50值分别为 93 nM 和 3 nM。12b还显示出对 ROCK 的相当大的选择性。12b的平均眼压降低效果在眼压正常模型中为 34.3%，未观察到明显的充血。总的来说，这项研究为针对青光眼的 ROCK 靶向药物发现提供了一个很好的起点。
• Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
  申请人：——

  公开号：US20030166932A1

  公开（公告）日：2003-09-04

  Compounds of the formula 1 where the symbols are as defined in the specification, have retinoid agonist, antagonist or negative hormone-like biological activity.

  式中符号如规范中定义，具有视黄醇激动剂、拮抗剂或负激素样生物活性。
• Discovery of 3,4-Dihydrobenzo[<i>f</i>][1,4]oxazepin-5(2<i>H</i>)-one Derivatives as a New Class of Selective TNIK Inhibitors and Evaluation of Their Anti-Colorectal Cancer Effects
  作者：Yueshan Li、Liting Zhang、Ruicheng Yang、Zeen Qiao、Ming Wu、Chong Huang、Chenyu Tian、Xinling Luo、Wei Yang、Yun Zhang、Linli Li、Shengyong Yang

  DOI：10.1021/acs.jmedchem.1c00672

  日期：2022.2.10

  colorectal cancer (CRC) that is often associated with dysregulation of Wnt/β-catenin signaling pathway. Herein, we report the discovery of a series of 3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one derivatives as a new class of TNIK inhibitors. Structure–activity relationship (SAR) analyses led to the identification of a number of potent TNIK inhibitors with compound 21k being the most active one (IC50:

  Traf2 和 Nck 相互作用蛋白激酶 (TNIK) 是 Wnt/β-catenin 通路的下游信号蛋白，被认为是治疗结直肠癌 (CRC) 的潜在靶点，结直肠癌通常与Wnt/β-连环蛋白信号通路。在此，我们报告发现了一系列 3,4-二氢苯并[ f ][1,4]oxazep​​in-5(2 H )-one 衍生物作为一类新型 TNIK 抑制剂。构效关系 (SAR) 分析鉴定出许多有效的 TNIK 抑制剂，其中化合物21k是最活跃的一种 (IC 50 : 0.026 ± 0.008 μM)。该化合物还对 TNIK 对 406 种其他激酶表现出优异的选择性。在体外试验中，化合物21k可以有效抑制 CRC 细胞增殖和迁移，并在 HCT116 异种移植小鼠模型中表现出相当大的抗肿瘤活性。它还显示出良好的药代动力学特性。总体而言， 21k可能是针对 TNIK 药物发现的有前途的先导化合物，值得进一步研究。
• [EN] CHEMOKING RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE CHIMIOKINES
  申请人：ABBOTT LAB

  公开号：WO2013010453A1

  公开（公告）日：2013-01-24

  Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

  本文揭示了化学受体拮抗剂的化学式(I)，其中G1、X1、X2和X3如规范中所定义。还描述了包含这种化合物的组合物；以及使用这种化合物和组合物治疗疾病和疾病的方法。